Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue The Lancet Année : 2024

Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial

Bernard Goichot
  • Fonction : Auteur
Florina Luca
  • Fonction : Auteur
Alfredo Berruti
  • Fonction : Auteur
Deborah Cosentini
  • Fonction : Auteur
Sandrine Laboureau
  • Fonction : Auteur
Svenja Nölting
  • Fonction : Auteur
Felix Beuschlein
  • Fonction : Auteur
Christelle de la Fouchardière
  • Fonction : Auteur
Tina Kienitz
  • Fonction : Auteur
Timo Deutschbein
  • Fonction : Auteur
Stefanie Hahner
  • Fonction : Auteur
Martin Fassnacht
  • Fonction : Auteur
Stefania Zovato
  • Fonction : Auteur
Henri Timmers
  • Fonction : Auteur
Patricia Niccoli
  • Fonction : Auteur
Antongiulio Faggiano
  • Fonction : Auteur
Christine Docao
  • Fonction : Auteur
Delphine Drui
  • Fonction : Auteur
Francoise Borson Chazot
  • Fonction : Auteur
Olivier Chabre
  • Fonction : Auteur
Delphine Vezzosi
  • Fonction : Auteur
Frederic Castinetti
  • Fonction : Auteur
Jérôme Bertherat
  • Fonction : Auteur
Rossella Libé
  • Fonction : Auteur
Anne Paule Gimenez-Roqueplo
  • Fonction : Auteur
Judith Favier
  • Fonction : Auteur
Marcus Quinkler
  • Fonction : Auteur
Christian Strasburger
  • Fonction : Auteur
Katrin Zopf
  • Fonction : Auteur
Martin Reincke
  • Fonction : Auteur
Matthias Kroiss
  • Fonction : Auteur
Hanna Remde
  • Fonction : Auteur
Michaela Haaf
  • Fonction : Auteur
Carmina T. Fuß
  • Fonction : Auteur
Ulrich Dischinger
  • Fonction : Auteur
Graeme Eisenhofer
  • Fonction : Auteur
Christina Pamporaki
  • Fonction : Auteur
Anouk van Berkel
  • Fonction : Auteur

Résumé

© 2024 Elsevier LtdBackground: No randomised controlled trial has ever been done in patients with metastatic phaeochromocytomas and paragangliomas. Preclinical and first clinical evidence suggested beneficial effects of sunitinib. We aimed to evaluate the safety and efficacy of sunitinib in patients with metastatic phaeochromocytomas and paragangliomas. Methods: FIRSTMAPPP is a multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial done at 14 academic centres across four European countries. Eligible participants were adults (aged ≥18 years) with sporadic or inherited progressive metastatic phaeochromocytomas and paragangliomas. Patients were randomly assigned (1:1) to receive either oral sunitinib (37·5 mg per day) or placebo. Randomisation was stratified according to SDHB status (mutation present vs wild type) and number of previous systemic therapies (0 vs ≥1). Primary endpoint was the rate of progression-free survival at 12 months according to real-time central review (Response Evaluation Criteria in Solid Tumours version 1.1). On the basis of a two-step Simon model, we aimed for the accrual of 78 patients, assuming a 20% improvement of the 12-month progression-free survival rate from 20% to 40%, to conclude that sunitinib is effective. Crossover from the placebo group was allowed. This trial is registered with ClinicalTrials.gov, number NCT01371201, and is closed for enrolment. Findings: From Dec 1, 2011, to Jan 31, 2019, a total of 78 patients with progressive metastatic phaeochromocytomas and paragangliomas were enrolled (39 patients per group). 25 (32%) of 78 patients had germline SDHx variants and 54 (69%) had used previous therapies. The primary endpoint was met, with a 12-month progression-free survival in 14 of 39 patients (36% [90% CI 23u201350]) in the sunitinib group. In the placebo group, the 12-month progression-free survival in seven of 39 patients was 19% (90% CI 11u201331), validating the hypotheses of our study design. The most frequent grade 3 or 4 adverse events were asthenia (seven [18%] of 39 and one [3%] of 39), hypertension (five [13%] and four [10%]), and back or bone pain (one [3%] and three [8%]) in the sunitinib and placebo groups, respectively. Three deaths occurred in the sunitinib group: these deaths were due to respiratory insufficiency, amyotrophic lateral sclerosis, and rectal bleeding. Only the latter event was considered drug related. Two deaths occurred in the placebo group due to aspiration pneumonia and septic shock. Interpretation: This first randomised trial supports the use of sunitinib as the medical option with the highest level of evidence for anti-tumour efficacy in progressive metastatic phaeochromocytomas and paragangliomas. Funding: French Ministry of Health, through the National Institute for Cancer, German Ministry of Education and Research, and the German Research Foundation within the CRC/Transregio 205/2, EU Seventh Framework Programme, and a private donator grant.
Fichier non déposé

Dates et versions

hal-04616709 , version 1 (19-06-2024)

Identifiants

Citer

Eric Baudin, Julien Hadoux, Salma Moalla, Livia Lamartina, Marie Attard, et al.. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet, 2024, 403 (10431), pp.1061-1070. ⟨10.1016/S0140-6736(23)02554-0⟩. ⟨hal-04616709⟩
4 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More